Familial clear cell renal cell carcinoma (FCRC): Clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes

Journal of Medical Genetics

Volumn 37, Issue 5, 2000, Pages 348-353

  Woodward, Emma R ^a   Clifford, Steven C ^b   Astuti, Dewi ^b   Affara, Nabeel A ^a   Maher, Eamonn R ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CUL2; Familial clear cell renal carcinoma; MET; VHL

Indexed keywords

GENE PRODUCT;

ADULT; AGED; ARTICLE; CHROMOSOME TRANSLOCATION 3; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; FAMILIAL CANCER; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GERM CELL TUMOR; HUMAN; KIDNEY CARCINOMA; ONSET AGE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0034026499     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.37.5.348     Document Type: Article

References (44)

1. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Path Res Pract 1986;181:125-43.
2. Maher ER. Inherited renal cell carcinoma. Br J Urol 1996;78:542-5.
3. Maher ER, Yates JRW, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-63.
4. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 1993;260:1317-20.
5. Brauch H, Kishida T, Glavac D, et al. Von Hippel-Lindau disease with phaeochromocytoma in the Black Forest region in Germany: evidence for a founder effect. Hum Genet 1995;95:551-6.
6. Chen F, Slife L, Kishida T, Mulvihill S, Tisherman E, Zbar B. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. J Med Genet 1996;33:716-17.
7. Crossey PA, Eng C, Ginalska-Malinowska M, et al. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet 1995;32:885-6.
8. Neumann HPH, Eng C, Mulligan LM, et al. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia type 2. JAMA 1995;274:1149-51.
9. Woodward ER, Eng C, McMahon R, et al. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet 1997; 7:1051-6.
10. Maher ER, Yates JRW. Familial renal cell carcinoma - clinical and molecular genetic aspects. Br J Cancer 1991;63: 176-9.
11. Cohen AJ, Li FP, Berg S, et al. Hereditary renal cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592-5.
12. Kovacs G, Brusa P, De Riese W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 1989;43: 422-7.
13. Li FP, Decker HJH, Zbar B, et al. Clinical and genetic studies of renal cell carcinoma in a family with a constitutional chromosome 3;8 translocation. Ann Intern Med 1993;118: 106-11.
14. Zbar B, Glenn G, Lubcnsky I, et al. Hereditary papillary renal cell carcinoma, clinical studies in 10 families, J Urol 1995;153:907-12.
15. Schmidt L, Duh FM, Chen F, et al. Germlme and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
16. Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998;58:1719-22.
17. Teh B, Giraud S, Sari F, et al. Familial non-VHL non-papillary clear-cell renal cancer. Lancet 1997;349:848-9.
18. Maher ER, Yatcs JRW, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet 1990;27:311-14.
19. Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996;33:328-32.
20. Clifford SC, Walsh S, Hewson K, et al. Genomic structure and chromosomal localisation of the human CUL2 gene and mutation analysis of von Hippel-Lindau tumour suppressor-associated proteins (CUL2 and VBP-1) in renal cell carcinoma. Genes Chrom Cancer (in press).
21. Duerr EM, Gimm O, Kum JB, et al. Differences in allelic distribution of two polymorphisms in the VHL-associated gene CUL2 in pheochromocytoma patients without somatic CUL2 mutations. J Clin Endocrinol Metab (in press).
22. Richards FM, Webster AR, McMahon R, Woodward ER, Rose S, Maher ER. Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med 1998;243:527-33.
23. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-23.
24. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
25. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
26. Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852-5.
27. van-den-Berg A, Dijkhuizen Tj Draaijers TG, et al. Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. Genes Chrom Cancer 1997;19: 228-32.
28. Clifford SC, Prowse AH, Affara NA, Buys CHCM, Maher ER, Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHLindependent pathway in clear cell renal tumourigenesis. Genes Chrom Cancer 1998;22:200-9.
29. Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997;71:27-92.
30. Shimizu M, Yokota J, Mori N, et al. Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. Oncogene 1990;5:185-94.
31. Lott ST, Lovell M, Naylor SL, Killary AM. Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. Cancer Res 1998; 58:3533-7.
32. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint is abnormal in digestive tract cancers. Cell 1996;84:587-97.
33. Bugert P, Wilhelm M, Kovacs G. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinoma. Genes Chrom Cancer 1997;20:9-15.
34. van den Berg A, Draaijers TG, Kok K, et al. Normal FHIT transcripts in renal cell cancer- and lung cancer-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. Genes Chrom Cancer 1997;19: 220-7.
35. Kinzler KW, Vogeistein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
36. Maher ER, Kaelin WG. von Hippel-Lindau disease. Medicine 1997;76:381-91.
37. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor suppressor product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997;94:2156-61.
38. Longergan KM, Iliopoulos O, Ohh M, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cu12. Mol Cell Biol 1998;18: 732-41.
39. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-elonginC-elonginB, complex: implications for VHL tumor suppressor function. Science 1999;284:455-61.
40. Kamura T, Koepp DM, Conrad MN, et al. Rbxl, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-61.
41. Maxwell P, Wiesener M, Chang GW, et al The von Hippel-Lindau gene product is necessary for oxygen-dependent proteolysis of hypoxia-inducible factor a subunits. Nature 1999;399:271-5.
42. Gemmill RM, West JD, Boldog F, et al. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8, Proc Natl Acad Sci USA 1998;95: 9572-7.
43. Schmidt L, Li F, Brown RS, et al. Mechanism of turnorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am 1995;1: 191-6.
44. Bodmer D, Eleveld MJ, Ligtenberg MJL, et al. An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am J Hum Genet 1998;62:1475-83.